Peptides
The Next GLP-1 Frontier: Oral Pills, Muscle Loss, and the Mind
As the GLP-1 class expands beyond weekly injections, three new studies sketch a more complicated risk-benefit map than the headline weight-loss numbers suggest.
Peptides
Objective coverage of peptide science, mechanisms, clinical research, and the evolving regulatory and therapeutic landscape.
Peptides
Semaglutide's Cardiovascular Dividend: What the Latest Meta-Analyses Reveal
Two fresh syntheses sharpen the picture of how the most-talked-about GLP-1 protects the heart — and where the evidence still has gaps.
Peptides
The Quiet Risk in the Peptide Boom: Immunogenicity and What Compounding Pharmacies Don't Test For
Synthetic peptides now account for more than 1 in 10 new FDA-approved chemical entities. The frontier safety question isn't potency — it's what your immune system makes of the molecule, and the impurities riding alongside it.
Peptides
The Next GLP-1s: Dual Fatty-Acid Conjugates and Combo Therapies Push Past Semaglutide
Two 2025 preclinical studies hint at where this class is heading — longer-acting molecules, beta-cell-protective stacks, and the first real challengers to semaglutide's throne.
Peptides
Why GLP-1 Drugs Last for Days: The Lipid Trick Behind Semaglutide's Half-Life
Native GLP-1 vanishes from your bloodstream in minutes. A fatty-acid tail turns it into a once-weekly shot — but the same trick that buys time also makes the drug harder to manufacture.
Peptides
Peptides Go Programmable: AI Diffusion Models Are Designing the Next Therapeutic Wave
A new class of generative models is treating peptide design like a search problem — and the early outputs hint at a faster, more targeted pipeline behind a quarter of all pharma.
Peptides
The GLP-1 Side-Effect File: New Signals on Surgery, Pancreatitis, and the Gallbladder
Semaglutide and tirzepatide are reshaping body composition for millions of lifters and dieters. A cluster of 2025 reports is starting to map what happens when these drugs collide with surgery, scopes, and scans.
Peptides
Could a Pill Replace the Injection? The Race to Deliver Peptides Without Needles
GLP-1s rewrote metabolic medicine, but the syringe is still the weak link. New buccal devices and oral formulations are trying to close the gap — and the data is finally getting interesting.
Peptides
Tirzepatide vs. the GLP-1 Field: What the Switching Data Actually Shows
Patients are shuffling between Ozempic, dulaglutide, and tirzepatide. A small case series and a new biosimilar trial offer the first grounded signals on how this class is fragmenting — and what switching really looks like.
Peptides
GLP-1s Beyond Diabetes: New Meta-Analysis Maps Cardiovascular and Gynecologic Frontiers
A 2025 meta-analysis of 29 randomized trials suggests GLP-1 receptor agonists trim cardiovascular events in non-diabetic adults with obesity — while parallel reviews push the class into PCOS, perioperative care, and an experimental dual-receptor frontier.